EPS8 inhibition increases cisplatin sensitivity in lung cancer cells

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Gorsic, Lidija K ^a   Stark, Amy L ^a   Wheeler, Heather E ^a   Wong, Shan S ^a   Im, Hae K ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CISPLATIN; EPS 8 PROTEIN; MITHRAMYCIN; MITHRAMYCIN A; PROTEIN; RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOBLASTOID CELL LINE; PROTEIN EXPRESSION; RNA INTERFERENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL LINE; CISPLATIN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PLICAMYCIN; RNA INTERFERENCE;

EID: 84893176914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082220     Document Type: Article

References (43)

1. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23. (Pubitemid 46137553)
2. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, et al. (2007) Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 81: 427-437. (Pubitemid 47330203)
3. O'Donnell PH, Gamazon E, Zhang W, Stark AL, Kistner-Griffin EO, et al. (2010) Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics 20: 327-337.
4. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, et al. (2013) Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 13: 35-43.
5. Cox NJ, Gamazon ER, Wheeler HE, Dolan ME (2012) Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther 92: 425-427.
6. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, et al. (2011) Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 17: 5490-5500.
7. Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, et al. (2011) Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 17: 5801-5811.
8. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, et al. (2011) Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 157: 265-272.
9. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, et al. (2013) Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 19: 491-499.
10. Ricci MS, Zong WX (2006) Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11: 342-357.
11. Roos WP, Kaina B (2012) DNA damage-induced apoptosis: From specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett.
12. Wen Y, Gorsic LK, Wheeler HE, Ziliak DM, Huang RS, et al. (2011) Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics 21: 476-488.
13. Chen YJ, Shen MR, Maa MC, Leu TH (2008) Eps8 decreases chemosensitivity and affects survival of cervical cancer patients. Mol Cancer Ther 7: 1376-1385.
14. Ding X, Zhou F, Wang F, Yang Z, Zhou C, et al. (2013) Eps8 promotes cellular growth of human malignant gliomas. Oncol Rep 29: 697-703.
15. Liu PS, Jong TH, Maa MC, Leu TH (2010) The interplay between Eps8 and IRSp53 contributes to Src-mediated transformation. Oncogene 29: 3977-3989.
16. Zhang W, Duan S, Bleibel WK, Wisel SA, Huang RS, et al. (2009) Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet 125: 81-93.
17. Shukla SJ, Duan S, Badner JA, Wu X, Dolan ME (2008) Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics 18: 253-262. (Pubitemid 351323240)
18. Wen Y, Gamazon ER, Bleibel WK, Wing C, Mi S, et al. (2012) An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet 21: 1470-1480.
19. Matoskova B, Wong WT, Salcini AE, Pelicci PG, Di Fiore PP (1995) Constitutive phosphorylation of eps8 in tumor cell lines: relevance to malignant transformation. Mol Cell Biol 15: 3805-3812.
20. Lanzetti L, Rybin V, Malabarba MG, Christoforidis S, Scita G, et al. (2000) The Eps8 protein coordinates EGF receptor signalling through Rac and trafficking through Rab5. Nature 408: 374-377.
21. Chen H, Wu X, Pan ZK, Huang S (2010) Integrity of SOS1/EPS8/ABI1 tricomplex determines ovarian cancer metastasis. Cancer Res 70: 9979-9990.
22. Yang TP, Chiou HL, Maa MC, Wang CJ (2010) Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact 183: 181-186.
23. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477. (Pubitemid 46595760)
24. Majee S, Dasgupta D, Chakrabarti A (1999) Interaction of the DNA-binding antitumor antibiotics, chromomycin and mithramycin with erythroid spectrin. Eur J Biochem 260: 619-626. (Pubitemid 29148626)
25. Elias EG, Evans JT (1972) Mithramycin in the treatment of Paget's disease of bone. J Bone Joint Surg Am 54: 1730-1736.
26. Brown JH, Kennedy BJ (1965) Mithramycin in the Treatment of Disseminated Testicular Neoplasms. N Engl J Med 272: 111-118.
27. Ryan WG, Schwartz TB, Perlia CP (1969) Effects of mithramycin on Paget's disease of bone. Trans Assoc Am Physicians 82: 353-362.
28. Robins PR, Jowsey J (1973) Effect of mithramycin on normal and abnormal bone turnover. J Lab Clin Med 82: 576-586.
29. Nunez LE, Nybo SE, Gonzalez-Sabin J, Perez M, Menendez N, et al. (2012) A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis. J Med Chem 55: 5813-5825.
30. Remsing LL, Gonzalez AM, Nur-e-Alam M, Fernandez-Lozano MJ, Brana AF, et al. (2003) Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J Am Chem Soc 125: 5745-5753. (Pubitemid 36592899)
31. Barcelo F, Scotta C, Ortiz-Lombardia M, Mendez C, Salas JA, et al. (2007) Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences. Nucleic Acids Res 35: 2215-2226. (Pubitemid 47073709)
32. Barcelo F, Ortiz-Lombardia M, Martorell M, Oliver M, Mendez C, et al. (2010) DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry 49: 10543-10552.
33. Lee TJ, Jung EM, Lee JT, Kim S, Park JW, et al. (2006) Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 5: 2737-2746. (Pubitemid 44849000)
34. Shiota M, Yokomizo A, Kashiwagi E, Tada Y, Inokuchi J, et al. (2010) Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Sci 101: 1177-1185.
35. Wang H, Teh MT, Ji Y, Patel V, Firouzabadian S, et al. (2010) EPS8 upregulates FOXM1 expression, enhancing cell growth and motility. Carcinogenesis 31: 1132-1141.
36. Myatt SS, Lam EW (2007) The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7: 847-859. (Pubitemid 350006253)
37. Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL (2010) Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol Ther 9: 1008-1016.
38. Wierstra I, Alves J (2007) FOXM1c and Sp1 transactivate the P1 and P2 promoters of human c-myc synergistically. Biochem Biophys Res Commun 352: 61-68. (Pubitemid 44821094)
39. Maa MC, Lee JC, Chen YJ, Chen YJ, Lee YC, et al. (2007) Eps8 facilitates cellular growth and motility of colon cancer cells by increasing the expression and activity of focal adhesion kinase. J Biol Chem 282: 19399-19409.
40. Singh A, Ye M, Bucur O, Zhu S, Tanya Santos M, et al. (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 21: 1140-1152.
41. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, et al. (2008) ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-148. (Pubitemid 351194043)
42. Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, et al. (2009) Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther 8: 1536-1546.
43. Gaughan EM, Costa DB (2011) Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 3: 113-125.